UBX
Price
$1.45
Change
+$0.01 (+0.69%)
Updated
Sep 16, 09:44 AM (EDT)
XFOR
Price
$0.72
Change
+$0.01 (+1.41%)
Updated
Sep 16, 09:49 AM (EDT)
52 days until earnings call
Ad is loading...

UBX vs XFOR

Header iconUBX vs XFOR Comparison
Open Charts UBX vs XFORBanner chart's image
Unity Biotechnology
Price$1.45
Change+$0.01 (+0.69%)
Volume$3K
CapitalizationN/A
X4 Pharmaceuticals
Price$0.72
Change+$0.01 (+1.41%)
Volume$330
CapitalizationN/A
View a ticker or compare two or three
UBX vs XFOR Comparison Chart
Loading...
UBX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
UBX vs. XFOR commentary
Sep 16, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is UBX is a Sell and XFOR is a Hold.

COMPARISON
Comparison
Sep 16, 2024
Stock price -- (UBX: $1.44 vs. XFOR: $0.71)
Brand notoriety: UBX and XFOR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: UBX: 107% vs. XFOR: 64%
Market capitalization -- UBX: $24.26M vs. XFOR: $119.63M
UBX [@Biotechnology] is valued at $24.26M. XFOR’s [@Biotechnology] market capitalization is $119.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $606.91B to $0. The average market capitalization across the [@Biotechnology] industry is $3.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

UBX’s FA Score shows that 0 FA rating(s) are green whileXFOR’s FA Score has 0 green FA rating(s).

  • UBX’s FA Score: 0 green, 5 red.
  • XFOR’s FA Score: 0 green, 5 red.
According to our system of comparison, XFOR is a better buy in the long-term than UBX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

UBX’s TA Score shows that 3 TA indicator(s) are bullish while XFOR’s TA Score has 5 bullish TA indicator(s).

  • UBX’s TA Score: 3 bullish, 7 bearish.
  • XFOR’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XFOR is a better buy in the short-term than UBX.

Price Growth

UBX (@Biotechnology) experienced а -0.69% price change this week, while XFOR (@Biotechnology) price change was +8.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.56%. For the same industry, the average monthly price growth was +4.67%, and the average quarterly price growth was -1.44%.

Reported Earning Dates

UBX is expected to report earnings on May 09, 2023.

XFOR is expected to report earnings on Nov 07, 2024.

Industries' Descriptions

@Biotechnology (+2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XFOR($120M) has a higher market cap than UBX($24.3M). XFOR YTD gains are higher at: -15.325 vs. UBX (-25.389). XFOR has higher annual earnings (EBITDA): 25.7M vs. UBX (-28.64M). XFOR has more cash in the bank: 169M vs. UBX (34M). UBX has less debt than XFOR: UBX (21.7M) vs XFOR (78.2M). XFOR has higher revenues than UBX: XFOR (563K) vs UBX (0).
UBXXFORUBX / XFOR
Capitalization24.3M120M20%
EBITDA-28.64M25.7M-111%
Gain YTD-25.389-15.325166%
P/E RatioN/A5.46-
Revenue0563K-
Total Cash34M169M20%
Total Debt21.7M78.2M28%
FUNDAMENTALS RATINGS
UBX vs XFOR: Fundamental Ratings
UBX
XFOR
OUTLOOK RATING
1..100
7583
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
65
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9843
PRICE GROWTH RATING
1..100
6163
P/E GROWTH RATING
1..100
10045
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

UBX's Valuation (48) in the Biotechnology industry is in the same range as XFOR (65). This means that UBX’s stock grew similarly to XFOR’s over the last 12 months.

UBX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as XFOR (100). This means that UBX’s stock grew similarly to XFOR’s over the last 12 months.

XFOR's SMR Rating (43) in the Biotechnology industry is somewhat better than the same rating for UBX (98). This means that XFOR’s stock grew somewhat faster than UBX’s over the last 12 months.

UBX's Price Growth Rating (61) in the Biotechnology industry is in the same range as XFOR (63). This means that UBX’s stock grew similarly to XFOR’s over the last 12 months.

XFOR's P/E Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for UBX (100). This means that XFOR’s stock grew somewhat faster than UBX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
UBXXFOR
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
86%
Momentum
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
75%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 22 days ago
77%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
86%
Bearish Trend 5 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
UBX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CURLF2.920.09
+3.18%
Curaleaf Hldgs Inc.
ASMLF809.9012.64
+1.59%
ASML Holding N.V.
SCTSF0.13N/A
+0.95%
SCOTTIE RES CORP.
HENOY22.260.08
+0.36%
Henkel AG & Co. KGAA
BZLFY48.06-0.03
-0.06%
Bunzl plc

UBX and

Correlation & Price change

A.I.dvisor indicates that over the last year, UBX has been loosely correlated with NCNA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if UBX jumps, then NCNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UBX
1D Price
Change %
UBX100%
+2.86%
NCNA - UBX
42%
Loosely correlated
-0.39%
KOD - UBX
37%
Loosely correlated
+13.87%
VTGN - UBX
35%
Loosely correlated
+3.13%
XFOR - UBX
35%
Loosely correlated
+4.72%
CHRS - UBX
35%
Loosely correlated
+0.78%
More

XFOR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XFOR has been loosely correlated with KROS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if XFOR jumps, then KROS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XFOR
1D Price
Change %
XFOR100%
+4.72%
KROS - XFOR
42%
Loosely correlated
+1.03%
COGT - XFOR
41%
Loosely correlated
+3.51%
CDXS - XFOR
37%
Loosely correlated
+1.83%
UBX - XFOR
35%
Loosely correlated
+2.86%
BEAM - XFOR
35%
Loosely correlated
+7.79%
More